BR112022019393A2 - Vetor de expressão de polipeptídeo de ligação ao antígeno biespecífico, método para construir o mesmo, biblioteca de exibição de polipeptídeo de ligação ao antígeno biespecífico e método para triagem de anticorpos ou fragmentos de anticorpos - Google Patents

Vetor de expressão de polipeptídeo de ligação ao antígeno biespecífico, método para construir o mesmo, biblioteca de exibição de polipeptídeo de ligação ao antígeno biespecífico e método para triagem de anticorpos ou fragmentos de anticorpos

Info

Publication number
BR112022019393A2
BR112022019393A2 BR112022019393A BR112022019393A BR112022019393A2 BR 112022019393 A2 BR112022019393 A2 BR 112022019393A2 BR 112022019393 A BR112022019393 A BR 112022019393A BR 112022019393 A BR112022019393 A BR 112022019393A BR 112022019393 A2 BR112022019393 A2 BR 112022019393A2
Authority
BR
Brazil
Prior art keywords
binding polypeptide
bispecific antigen
antibodies
expression vector
display library
Prior art date
Application number
BR112022019393A
Other languages
English (en)
Inventor
Zhou Chen
Original Assignee
Ddbio Co Ltd Shang Hai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ddbio Co Ltd Shang Hai filed Critical Ddbio Co Ltd Shang Hai
Publication of BR112022019393A2 publication Critical patent/BR112022019393A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y605/00—Ligases forming phosphoric ester bonds (6.5)
    • C12Y605/01—Ligases forming phosphoric ester bonds (6.5) forming phosphoric ester bonds (6.5.1)
    • C12Y605/01001—DNA ligase (ATP) (6.5.1.1)
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

VETOR DE EXPRESSÃO DE POLIPEPTÍDEO DE LIGAÇÃO AO ANTÍGENO BIESPECÍFICO, MÉTODO PARA CONSTRUIR O MESMO, BIBLIOTECA DE EXIBIÇÃO DE POLIPEPTÍDEO DE LIGAÇÃO AO ANTÍGENO BIESPECÍFICO E MÉTODO PARA TRIAGEM DE ANTICORPOS OU FRAGMENTOS DE ANTICORPOS. É fornecido um método para construir um vetor de expressão de polipeptídeo de ligação ao antígeno biespecífico e o vetor de expressão de polipeptídeo de ligação ao antígeno biespecífico produzido, de acordo com o método. O método compreende: realizar o tratamento usando endonuclease de restrição de um sítio de corte de enzima de reconhecimento específico para obter sete fragmentos de ácido nucleico com extremidades coesivas específicas e ligar direcionalmente os fragmentos de ácido nucleico. Além disso, é fornecido um método para estabelecer uma biblioteca de exibição de polipeptídeos usando o vetor de expressão. A biblioteca de exibição pode ser usada para triagem eficaz de anticorpos ou fragmentos de anticorpos.
BR112022019393A 2020-03-27 2021-03-26 Vetor de expressão de polipeptídeo de ligação ao antígeno biespecífico, método para construir o mesmo, biblioteca de exibição de polipeptídeo de ligação ao antígeno biespecífico e método para triagem de anticorpos ou fragmentos de anticorpos BR112022019393A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010228279 2020-03-27
PCT/CN2021/083248 WO2021190631A1 (zh) 2020-03-27 2021-03-26 在哺乳动物细胞表面展示双特异性抗体的方法及载体

Publications (1)

Publication Number Publication Date
BR112022019393A2 true BR112022019393A2 (pt) 2022-12-06

Family

ID=77891328

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022019393A BR112022019393A2 (pt) 2020-03-27 2021-03-26 Vetor de expressão de polipeptídeo de ligação ao antígeno biespecífico, método para construir o mesmo, biblioteca de exibição de polipeptídeo de ligação ao antígeno biespecífico e método para triagem de anticorpos ou fragmentos de anticorpos

Country Status (8)

Country Link
US (1) US20230331871A1 (pt)
EP (1) EP4129332A4 (pt)
JP (1) JP2023518898A (pt)
KR (1) KR20220160130A (pt)
CN (1) CN115315271A (pt)
BR (1) BR112022019393A2 (pt)
MX (1) MX2022012005A (pt)
WO (1) WO2021190631A1 (pt)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101210241A (zh) * 2006-12-27 2008-07-02 陕西超英生物科技有限公司 一种噬菌体基因工程抗体库基因组装的方法
US20120101000A1 (en) * 2008-11-21 2012-04-26 Chen Zhou High complexity mammalian display library and methods of screening
CN102978713B (zh) * 2012-11-23 2015-02-25 浙江大学 一种白血病单链抗体库及其构建方法和应用
SG10201913676QA (en) * 2017-04-01 2020-03-30 Beijing hanmi pharm co ltd Anti-pd-l1/anti-pd-1 natural antibody structure-like heterodimeric bispecific antibody and preparation thereof
EP3608339A4 (en) * 2017-04-07 2020-12-23 Kookmin University Industry Academy Cooperation Foundation ANTIBODY FC VARIANTS TO IMPROVE THE HALF-LIFE OF BLOOD
EP3793600A4 (en) * 2018-05-16 2022-05-11 Arbele Limited COMPOSITION OF BISPECIFIC ANTIBODIES AND METHOD OF USE THEREOF

Also Published As

Publication number Publication date
US20230331871A1 (en) 2023-10-19
WO2021190631A1 (zh) 2021-09-30
EP4129332A1 (en) 2023-02-08
MX2022012005A (es) 2022-10-21
CN115315271A (zh) 2022-11-08
KR20220160130A (ko) 2022-12-05
EP4129332A4 (en) 2024-04-24
JP2023518898A (ja) 2023-05-08

Similar Documents

Publication Publication Date Title
PE20181044A1 (es) Anticuerpos anti-pd-1 y composiciones
Schünemann et al. GRADE Evidence to Decision (EtD) frameworks for adoption, adaptation, and de novo development of trustworthy recommendations: GRADE-ADOLOPMENT
BR112017010744A2 (pt) anticorpos monoclonais anti-pd-1 e método de obtenção dos mesmos
BR112022019392A2 (pt) Vetor de exibição de gene de polipeptídeo de ligação específico de antígeno, métodos para construir o mesmo e para triar um polipeptídeo de ligação específico de antígeno ou fragmentos do mesmo, bem como biblioteca bacteriana de exibição de gene de polipeptídeo de ligação específico de antígeno
MY197648A (en) Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
CN110168105A (zh) 用于对t细胞受体进行测序的系统和方法及其用途
EA201691925A1 (ru) Биспецифические антитела, которые связываются с cd38 и cd3
MX2011001764A (es) Metodos, sistemas y productos para predecir la respuesta de las celulas tumorales a un agente terapeutico y tratar un paciente de acuerdo con la respuesta predicha.
BR112022019393A2 (pt) Vetor de expressão de polipeptídeo de ligação ao antígeno biespecífico, método para construir o mesmo, biblioteca de exibição de polipeptídeo de ligação ao antígeno biespecífico e método para triagem de anticorpos ou fragmentos de anticorpos
Vax et al. Distributed Agile: Growing a practice together
CA3215778A1 (en) Engineering of antigen-binding proteins
AR126387A1 (es) Anticuerpos anti-tnfr2 y usos de estos
Mosalman Yazdi et al. Delay determination of subway construction project by fuzzy MCDM (case study, karaj subway)
Codina et al. Insights into the stability of a therapeutic antibody Fab fragment by molecular dynamics and its stabilization by computational design
PE20220763A1 (es) Materiales y metodos para modular la inmunidad mediada por celulas t
Anvarovich Creation of new production facilities on the basis of investments and increase of efficiency of their use
Indyk et al. Law Distance Learning Technique For Engineering University Students: Pros And Cons
Elmamoun et al. OP0312 International league of associations for rheumatology (ILAR) treatment recommendations for psoriatic arthritis in resource-poor countries
Ibraeva et al. ORGANIZATIONAL AND ECONOMIC MECHANISM OF FORMATION OF THE MACHINE-BUILDING CLUSTER
Capone et al. Artificial Intelligence Models for Predicting Budget Expenditures
US20070005318A1 (en) System and method for chemical process simulations
Breckenridge et al. The evolving impact on survival outcomes in multiple myeloma with greater access to novel treatment regimens: experience in a real-world cohort
Nguyen Computational design targeting the androgen receptor, CCR8 receptor, and NSP15 enzyme
BR112022013977A2 (pt) Anticorpos, composição farmacêutica, ácido nucleico isolado, vetor, célula hospedeira, método de tratamento do câncer, processo para a produção de um anticorpo e reagente de diagnóstico
Işıkdağ et al. Modeling the trend of construction materials industry with NARNETs